| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 216.3 | 209.4 |
| Gross profit | 125.4 | 129.2 |
| Profit before tax | 7.9 | 43.4 |
| Net income | 21.8 | 31.5 |
| EPS (diluted, $ a share) | $0.60 | $0.84 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -30.9% |
|---|---|
| Revenue, year on year | +3.3% |
| Gross margin | 58.0% |
| Operating margin | 13.3% |
10-Q filed with the SEC, NASDAQ: COLL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Collegium Pharmaceutical, Inc: key numbers
- Share price
- $25.43Close, Nov 16
- Market cap
- $790M
- Shares outstanding
- 31.08MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Collegium Pharmaceutical, Inc
All →Collegium Pharmaceutical Financial Results
Collegium Pharmaceutical reported record Q3 2026 net revenue of $216.3 million, driven by strong performance in its ADHD portfolio, including record JORNAY PM sales and the first full quarter of AZSTARYS revenue. The company reaffirmed its full-year 2026 financial guidance and expects to complete its $50 million accelerated share repurchase program by year-end.
- Term
- Q3 2026
“We continued to see strong demand across our ADHD portfolio, supported by expanded commercial efforts heading into the back-to-school season. JORNAY PM reached record revenues, prescriptions and prescriber adoption, with quarterly net revenue growing 24% year-over-year.”
Vikram Karnani, President and Chief Executive Officer
“We generated a record $216.3 million in quarterly net revenue and $121.6 million in adjusted EBITDA, with our ADHD franchise now contributing more than 36% of total revenue.”
Colleen Tupper, Chief Financial Officer
Collegium Pharmaceutical Court & Legal Update
Collegium Pharmaceutical entered into a settlement agreement with Grünenthal GmbH to resolve patent infringement litigation related to Nucynta ER. As part of the settlement, Collegium will pay $17 million to terminate a 2015 license agreement and discharge all future royalty obligations. Additionally, Grünenthal assigned certain Nucynta-related patents to Collegium and moved to dismiss the pending lawsuit.
- Counterparty
- Grünenthal GmbH